Hologic, Inc. (HOLX) Earnings Per Share (EPS): 2.40
Is Hologic, Inc.’s earnings per share (EPS) high or low?
Hologic, Inc.'s earnings per share (EPS) of 2.40 is 41% below its 5-year average of 4.07, near the low end of its 5-year range (1.85–7.28).
The earnings per share (EPS) for Hologic, Inc. (HOLX) is 2.40 as of Wednesday, June 10, 2026. It is below its 12-month average by 17.95% (2.92).
HOLX Earnings Per Share (EPS) Chart
HOLX Average Earnings Per Share (EPS) Chart
HOLX Current vs Average Earnings Per Share (EPS) Chart
HOLX Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
2.40
EARNINGS PER SHARE (EPS) AVG TTM
2.92
EARNINGS PER SHARE (EPS) AVG 3Y
3.22
EARNINGS PER SHARE (EPS) AVG 5Y
4.07
EARNINGS PER SHARE (EPS) AVG 10Y
2.56
EARNINGS PER SHARE (EPS) AVG 15Y
1.50
EARNINGS PER SHARE (EPS) AVG 20Y
0.74
CURRENT VS TTM AVG
-17.95%
CURRENT VS 3Y AVG
-25.47%
CURRENT VS 5Y AVG
-40.98%
CURRENT VS 10Y AVG
-6.38%
CURRENT VS 15Y AVG
+60.13%
CURRENT VS 20Y AVG
+226.42%
HOLX Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 2.40 | 2.92 | 3.22 | 4.07 |
| Moderna, Inc. (MRNA) | $18.40B | -8.15 | -8.27 | -1.90 | 3.46 |
| Align Technology, Inc. (ALGN) | $12.56B | 5.96 | 5.64 | 5.43 | 9.01 |
| BioNTech SE (BNTX) | $21.81B | -5.94 | -4.08 | 9.21 | 14.48 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 42.71 | 41.42 | 39.43 | 36.04 |
| Baxter International Inc. (BAX) | $10.49B | -2.10 | -1.51 | -0.65 | 0.36 |
| Waters Corporation (WAT) | $23.83B | 7.87 | 10.78 | 11.05 | 10.65 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -3.76 | -1.35 | 4.03 | 5.21 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 6.07 | -18.74 | -45.28 | 14.90 |
| Veeva Systems Inc. (VEEV) | $26.73B | 5.61 | 4.98 | 4.09 | 3.61 |
EPS Comparison
Trailing EPS (TTM)
$2.40
Forward EPS (Est.)
$4.42
P/E Ratio
31.7
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
Hologic, Inc. Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The earnings per share (EPS) for HOLX stock is 2.40.
- Is Hologic, Inc.'s earnings per share (EPS) high or low?
- Hologic, Inc.'s earnings per share (EPS) of 2.40 is 41% below its 5-year average of 4.07, near the low end of its 5-year range (1.85–7.28).
- What is the TTM average earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The TTM average earnings per share (EPS) for HOLX stock is 2.92.
- What is the 3Y average earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The 3Y average earnings per share (EPS) for HOLX stock is 3.22.
- What is the 5Y average earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The 5Y average earnings per share (EPS) for HOLX stock is 4.07.
- What is the 10Y average earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The 10Y average earnings per share (EPS) for HOLX stock is 2.56.
- What is the 15Y average earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The 15Y average earnings per share (EPS) for HOLX stock is 1.50.
- What is the 20Y average earnings per share (EPS) for Hologic, Inc. (HOLX)?
- The 20Y average earnings per share (EPS) for HOLX stock is 0.74.
Hologic, Inc. Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-09-27 | 2.50 |
| 2024-09-30 | 3.35 |
| 2023-09-30 | 1.85 |
| 2022-09-30 | 5.18 |
| 2021-09-30 | 7.28 |
| 2020-09-30 | 4.24 |
| 2019-09-30 | -0.15 |
| 2018-09-30 | -0.40 |
| 2017-09-30 | 2.70 |
| 2016-09-30 | 1.18 |
| 2015-09-30 | 0.47 |
| 2014-09-30 | 0.06 |
| 2013-09-30 | -4.36 |
| 2012-09-30 | -0.28 |
| 2011-09-30 | 0.60 |
| 2010-09-30 | -0.24 |
| 2009-09-30 | -8.48 |
| 2008-09-30 | -1.57 |
| 2007-09-30 | 0.88 |
| 2006-09-30 | 0.30 |
| 2005-09-30 | 0.33 |
| 2004-09-30 | 0.15 |
| 2003-09-30 | 0.04 |
| 2002-09-30 | 0.00 |
| 2001-09-30 | -0.34 |
| 2000-09-30 | -0.30 |
| 1999-09-30 | -0.07 |
| 1998-09-30 | 0.20 |
| 1997-09-30 | 0.34 |
| 1996-09-30 | 0.24 |
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini